Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.

Robin Lin Miller(Michigan State University), W J Urba(Frederick National Laboratory for Cancer Research), Jeffrey W. Clark(Massachusetts General Hospital), Mary Jane Jones, John Edward McKnight, DL Longo, MJ Hawkins, J. W. Smith(Frederick National Laboratory for Cancer Research), Ronald G. Steis, Edward D. Crum
PubMed
April 1, 1989
Cited by 38

Related Papers

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
|The Lancet Oncology|2012|1.3k